Sökning: "Cancer detection"
Visar resultat 21 - 25 av 524 avhandlingar innehållade orden Cancer detection.
21. On the Use of 76Br-labelled Monoclonal Antibodies for PET : Preclinical Evaluation of Halogenated Antibodies for Diagnosis and Treatment of Cancer
Sammanfattning : Radioactive substances are used in vivo to localize and characterize malignant tumours, generally by scintigraphic methods. In this context positron emission tomography (PET) in combination with radiolabelled monoclonal antibodies (mAbs) may provide a sensitive and specific method for detection of cancer. LÄS MER
22. On the genetics of hereditary breast/ovarian cancer. BRCA1, BRCA2 and beyond
Sammanfattning : Breast cancer is the most common malignancy in women. Most of the breast cancers are sporadic with no apparent inheritance factor but about 5-10% is believed to be caused by an inherited predisposition. Aims: This thesis aimed at defining the BRCA1/2 mutation spectrum of the west Swedish population and specifically to characterize the BRCA1c. LÄS MER
23. Long-term survival and prognostic factors in endometrial cancer - a populationbased cohort study
Sammanfattning : Aims: The over-all aims of this thesis were to evaluate the associations between prognostic factors and excess mortality rate, between socioeconomic and immigrant status and incidence rate, in endometrioid (EEC) and non-endometrioid (NEC) endometrial carcinoma. Material and methods: Study I-III were retrospective population-based cohort studies including women resident in a defined geographical area, with endometrial carcinoma. LÄS MER
24. Molecular Characterization of Bladder Cancer Subtypes
Sammanfattning : Bladder cancer is one of the most common malignancies world-wide, and in Sweden approximately 3000 cases are diagnosed annually. Even though bladder cancer is so common there is low public awareness of the disease, and it has historically been less studied compared to other common types of cancer. LÄS MER
25. Targeting allelic loss in colorectal cancer
Sammanfattning : Targeted cancer therapy exploits molecular differences between tumor and normal cells to selectively kill cancer cells. Whereas targeting of activated oncogenes has proved clinically useful, few current therapies exploit loss-of-function mutations in tumor suppressor genes or in the genome at large. LÄS MER